European shares suffer worst day in 17 months on virus fears

* Travel stocks dive nearly 9%, worst performers this week

* Banks tumble, tracking bond yields

* Stay-at-home stocks gain ground (Updates to market close)

By Sruthi Shankar and Ambar Warrick

Nov 26 (Reuters) - European stocks plummeted amid widespread selling on Friday, as reports of a newly identified and possibly vaccine-resistant coronavirus variant stoked fears of a fresh hit to the global economy and drove investors out of riskier assets.

The benchmark STOXX 600 index .STOXX ended 3.7% down in its worst session since June 2020, while the volatility gauge .V2TX for the main stock market hit a near 10-month high.

The day's losses saw the STOXX 600 lose 4.5% this week.

Little is known of the variant detected in South Africa, Botswana and Hong Kong, but scientists said it has an unusual combination of mutations and may be able to evade immune responses or make it more transmissible.

France's CAC 40 .FCHI shed 4.8%. UK's FTSE 100 .FTSE dropped 3.6%, while Germany's DAX .GDAXI fell 4.2% and Spain's IBEX .IBEX lost 5.0%.

"With Europe and some northern parts of the U.S. in a stretched situation due to an already high number of new cases and hospitalisations, this new virus strain comes at the worst possible time," said Peter Garnry, head of equity strategy at Saxo Bank.

"Equities are reacting negatively because it is unknown at this point to what degree the vaccines will be effective against the new strain, and thus it increases risk of new lockdowns." Among the European stock sectors, travel and leisure .SXTP plummeted 8.8% in its worst day since the COVID-19 shock sell-off in March 2020.

Britain announced a temporary ban on flights from South Africa and several neighbouring countries from 1200 GMT on Friday. The European Union is also planning similar moves.

Travel stocks were the worst performers this week, down 13.6%. Concerns over rising COVID-19 cases had pulled European stock markets from record highs last week amid fears of more restrictions.

The virus scare prompted euro zone money markets to scale back bets of a rate hike from the European Central Bank next year. Odds of a 10 basis point rate hike in December 2022 almost halved from 100% earlier this week.

Euro zone government bond yields dropped, pressuring European bank stocks .SX7P , which lost 6.9%.

Oil & gas producers .SXEP slumped 5.8%, while miners .SXPP tumbled 5.0% as oil and metal prices lost ground as reports of the new virus variant fuelled economic slowdown worries.

The technology sector .SX8P had relatively smaller losses, thanks to gains in stay-at-home stocks. Defensives such as healthcare .SXDP and utilities .SX6P fell the least.

Reporting by Sruthi Shankar and Bansari Mayur Kamdar in Bengaluru; Editing by Subhranshu Sahu, Arun Koyyur and Emelia Sithole-Matarise

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.